FAQ: Branded Legacy's Intranasal Drug Delivery Platform Patent Filing

What is the main announcement from Branded Legacy, Inc.?

Branded Legacy announced that its subsidiary BioLegacy Evaluative Group Inc. has filed a provisional patent application with the U.S. Patent and Trademark Office for an ‘Air-Driven Unitary Intranasal Drug Delivery Device for Stable and Reconstitutable Medicaments.’ This is a compact, air-powered platform designed for precise intranasal drug delivery.

What types of medications can this device deliver?

The device is designed to provide precise dosing for both stable formulations such as naloxone and unstable drugs that require on-demand reconstitution. This makes it versatile for various medication types that need intranasal administration.

Why is this intranasal delivery platform significant?

This platform offers precise, reliable, and cost-effective intranasal dosing, which is particularly important for medications used in addiction treatment and harm reduction. It represents innovative progress in drug delivery technology that could improve treatment outcomes.

Who is developing this drug delivery technology?

The technology is being developed by BioLegacy Evaluative Group Inc., a subsidiary of Branded Legacy, Inc. The company collaborates with leading institutions including McMaster University and Stanford University to drive transformative research and innovation.

What manufacturing capabilities does Branded Legacy have?

Branded Legacy operates a state-of-the-art GMP manufacturing facility in Vancouver, which provides advanced production capabilities to deliver cutting-edge products. This supports their position as a leader in addressing critical public health challenges.

Where can I find more detailed information about this announcement?

The full press release can be viewed at https://ibn.fm/4ACgT. For more information about the company, visit their website at https://BrandedLegacy.com.

What is Branded Legacy’s primary business focus?

Branded Legacy is a forward-thinking holdings company dedicated to pioneering solutions in addiction treatment and harm reduction. They focus on innovative life sciences and wellness solutions through research and advanced manufacturing capabilities.

What stage is this patent application currently in?

The company has filed a provisional patent application with the U.S. Patent and Trademark Office. This is an initial step in the patent process that establishes an early filing date while allowing time to refine the invention.